Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Trends in Cancer Research   Volumes    Volume 9 
William Coley’s legacy - the development of modern mycobacteria-based therapies for cancer
Androulla Elia, Laura Rosa Brunet, Thorsten Hagemann
Pages: 109 - 117
Number of pages: 9
Trends in Cancer Research
Volume 9 

Copyright © 2013 Research Trends. All rights reserved

The recent successful use of immunotherapeutic agents for the treatment of cancer has provided further support for a role for the immune system in this disease and so, it is appropriate to remember the father of immunotherapy, William B. Coley, who started this journey in 1891. Coley, a surgeon with an interest in bone sarcoma, attempted to treat patients with inoperable bone and soft-tissue sarcoma with administrations of bacterial preparations. He developed a treatment that became known as Coley Toxins, which he used for over 40 years at the Bone Sarcoma Unit at Memorial Hospital, now the Memorial Sloan-Kettering Cancer Centre in New York City, surrounded by controversy and scepticism but achieving undeniable success. In this review we will outline the subsequent progress of his idea, including related adaptations, and explore alternatives such as heat-killed mycobacteria-based immunotherapies, which are being developed by the pharmaceutical industry. We will present evidence to explain the potential value of this approach and discuss its applicability to cancer immunotherapy.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms